Van Zwieten et al., 1995 - Google Patents
Muscarinic receptors and drugs in cardiovascular medicineVan Zwieten et al., 1995
- Document ID
- 5977502920708056803
- Author
- Van Zwieten P
- Doods H
- Publication year
- Publication venue
- Cardiovascular Drugs and Therapy
External Links
Snippet
The parasympathetic system and its associated muscarinic receptors have been the subject of a renaissance of interest for the following two main reasons:(1) the association of endothelial muscarinic receptors and the nitric oxide (NO) pathway;(2) the discovery of …
- 102000014415 Muscarinic acetylcholine receptor family 0 title abstract description 42
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Van Zwieten et al. | Muscarinic receptors and drugs in cardiovascular medicine | |
| Janis et al. | Sites of action of Ca2+ channel inhibitors | |
| DE60120494T2 (en) | SUBSTITUTES TRIAZOLDIAMINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | |
| CN1980677B (en) | Novel anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RYR2) and uses thereof | |
| WO2014127350A1 (en) | Modulators of vasopressin receptors with therapeutic potential | |
| EA007254B1 (en) | Compounds specific to adenosine a, aand areceptor and uses thereof | |
| KR20010087361A (en) | [1,2,4]-Triazolo[1,5-c]pyrimidine derivatives | |
| JP2004500355A (en) | Compounds, compositions and methods for stimulating neuron growth and elongation | |
| DE69131907T2 (en) | THIENODIAZEPINE COMPOUNDS AND THEIR USE | |
| EP2119704A1 (en) | Acylguanidine derivative | |
| JPH11507339A (en) | Alpha 1a adrenergic receptor antagonist | |
| JPS63119464A (en) | Novel substituted dihydropyridine derivative, its production, drug composed of said derivative and its production | |
| DE69811492T2 (en) | BENZONAPHTHYRIDINE | |
| US5418229A (en) | Muscarinic receptor antagonists | |
| US5475004A (en) | Angiotensin II receptor antagonists for the treatment and prophylaxis of coronary heart disease | |
| DE60121587T2 (en) | CYCLIC GMP SPECIFIC PHOSPHODIESTERASE INHIBITORS | |
| RO112505B1 (en) | DERIVATIVES OF 1, 2, 3-4-TETRAHYDROCYCLOPENT (b) INDOLES AND 1, 2, 3, 3a, 4,8a-HEXAHIDROCICLOPENT (b) SUBSTITUTES INDUSTRIES | |
| Katz | Selectivity and toxicity of antiarrhythmic drugs: molecular interactions with ion channels | |
| KR20140036305A (en) | Organic compounds | |
| WO2001032176A1 (en) | Beta-carboline derivatives for use as analgesics | |
| DE69420345T2 (en) | BENZOTHIAZOLESULFONAMIDE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND APPLICATIONS | |
| DE3735895A1 (en) | CONDENSED DIAZEPINONE, METHOD FOR THE PRODUCTION THEREOF AND MEDICAMENT CONTAINING THESE COMPOUNDS | |
| US20230144901A1 (en) | Sortilin antagonists for use in the treatment of diabetic retinopathy | |
| KR100196969B1 (en) | Condensed diazepinones, process for their preparation and pharmaceutical compositions containing them | |
| Chang et al. | Endothelium-dependent and-independent vasorelaxation induced by CIJ-3-2F, a novel benzyl-furoquinoline with antiarrhythmic action, in rat aorta |